OBJECTIVES: Clinical failures with cefazolin have been described in high-inoculum infections caused by methicillin-susceptible Staphylococcus aureus (MSSA) producing type A β-lactamase. We investigated the prevalence of the cefazolin inoculum effect (InE) in MSSA from South American hospitals, since cefazolin is used routinely against MSSA due to concerns about the in vivo efficacy of isoxazolyl penicillins. METHODS: MSSA isolates were recovered from bloodstream (n = 296) and osteomyelitis (n = 68) infections in two different multicentre surveillance studies performed in 2001-02 and 2006-08 in South American hospitals. We determined standard-inoculum (10(5)cfu/mL) and high-inoculum (10(7) cfu/mL) cefazolin MICs. PFGE was performed on all isolates that exhibited a cefazolin InE. Multilocus sequence typing (MLST) and sequencing of part of blaZ were performed on representative isolates. RESULTS: The overall prevalence of the cefazolin InE was 36% (131 isolates). A high proportion (50%) of MSSA isolates recovered from osteomyelitis infections exhibited the InE, whereas it was observed in 33% of MSSA recovered from bloodstream infections. Interestingly, Ecuador had the highest prevalence of the InE (45%). Strikingly, 63% of MSSA isolates recovered from osteomyelitis infections in Colombia exhibited the InE. MLST revealed that MSSA isolates exhibiting the InE belonged to diverse genetic backgrounds, including ST5, ST8, ST30 and ST45, which correlated with the prevalent methicillin-resistant S. aureus clones circulating in South America. Types A (66%) and C (31%) were the most prevalent β-lactamases. CONCLUSIONS: Our results show a high prevalence of the cefazolin InE associated with type A β-lactamase in MSSA isolates from Colombia and Ecuador, suggesting that treatment of deep-seated infections with cefazolin in those countries may be compromised.
OBJECTIVES: Clinical failures with cefazolin have been described in high-inoculum infections caused by methicillin-susceptible Staphylococcus aureus (MSSA) producing type A β-lactamase. We investigated the prevalence of the cefazolin inoculum effect (InE) in MSSA from South American hospitals, since cefazolin is used routinely against MSSA due to concerns about the in vivo efficacy of isoxazolyl penicillins. METHODS: MSSA isolates were recovered from bloodstream (n = 296) and osteomyelitis (n = 68) infections in two different multicentre surveillance studies performed in 2001-02 and 2006-08 in South American hospitals. We determined standard-inoculum (10(5)cfu/mL) and high-inoculum (10(7) cfu/mL) cefazolin MICs. PFGE was performed on all isolates that exhibited a cefazolin InE. Multilocus sequence typing (MLST) and sequencing of part of blaZ were performed on representative isolates. RESULTS: The overall prevalence of the cefazolin InE was 36% (131 isolates). A high proportion (50%) of MSSA isolates recovered from osteomyelitis infections exhibited the InE, whereas it was observed in 33% of MSSA recovered from bloodstream infections. Interestingly, Ecuador had the highest prevalence of the InE (45%). Strikingly, 63% of MSSA isolates recovered from osteomyelitis infections in Colombia exhibited the InE. MLST revealed that MSSA isolates exhibiting the InE belonged to diverse genetic backgrounds, including ST5, ST8, ST30 and ST45, which correlated with the prevalent methicillin-resistant S. aureus clones circulating in South America. Types A (66%) and C (31%) were the most prevalent β-lactamases. CONCLUSIONS: Our results show a high prevalence of the cefazolin InE associated with type A β-lactamase in MSSA isolates from Colombia and Ecuador, suggesting that treatment of deep-seated infections with cefazolin in those countries may be compromised.
Authors: Martin E Stryjewski; Lynda A Szczech; Daniel K Benjamin; Jula K Inrig; Zeina A Kanafani; John J Engemann; Vivian H Chu; Maria J Joyce; L Barth Reller; G Ralph Corey; Vance G Fowler Journal: Clin Infect Dis Date: 2006-12-08 Impact factor: 9.079
Authors: R Monina Klevens; Melissa A Morrison; Joelle Nadle; Susan Petit; Ken Gershman; Susan Ray; Lee H Harrison; Ruth Lynfield; Ghinwa Dumyati; John M Townes; Allen S Craig; Elizabeth R Zell; Gregory E Fosheim; Linda K McDougal; Roberta B Carey; Scott K Fridkin Journal: JAMA Date: 2007-10-17 Impact factor: 56.272
Authors: Esteban C Nannini; Martin E Stryjewski; Kavindra V Singh; Agathe Bourgogne; Tom H Rude; G Ralph Corey; Vance G Fowler; Barbara E Murray Journal: Antimicrob Agents Chemother Date: 2009-06-01 Impact factor: 5.191
Authors: Jennifer A Shuford; Kerryl E Piper; Melanie Hein; Andrej Trampuz; James M Steckelberg; Robin Patel Journal: Diagn Microbiol Infect Dis Date: 2006-02-08 Impact factor: 2.803
Authors: Jinnethe Reyes; Sandra Rincón; Lorena Díaz; Diana Panesso; Germán A Contreras; Jeannete Zurita; Carlos Carrillo; Adele Rizzi; Manuel Guzmán; Javier Adachi; Shahreen Chowdhury; Barbara E Murray; Cesar A Arias Journal: Clin Infect Dis Date: 2009-12-15 Impact factor: 9.079
Authors: Stefan Monecke; Geoffrey Coombs; Anna C Shore; David C Coleman; Patrick Akpaka; Michael Borg; Henry Chow; Margaret Ip; Lutz Jatzwauk; Daniel Jonas; Kristina Kadlec; Angela Kearns; Frederic Laurent; Frances G O'Brien; Julie Pearson; Antje Ruppelt; Stefan Schwarz; Elizabeth Scicluna; Peter Slickers; Hui-Leen Tan; Stefan Weber; Ralf Ehricht Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: Marin L Schweizer; Jon P Furuno; Anthony D Harris; J Kristie Johnson; Michelle D Shardell; Jessina C McGregor; Kerri A Thom; Sara E Cosgrove; George Sakoulas; Eli N Perencevich Journal: BMC Infect Dis Date: 2011-10-19 Impact factor: 3.090
Authors: Lina P Carvajal; Sandra Rincon; Aura M Echeverri; Jessica Porras; Rafael Rios; Karen M Ordoñez; Carlos Seas; Sara I Gomez-Villegas; Lorena Diaz; Cesar A Arias; Jinnethe Reyes Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: Kavindra V Singh; Truc T Tran; Esteban C Nannini; Vincent H Tam; Cesar A Arias; Barbara E Murray Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Esteban C Nannini; Kavindra V Singh; Cesar A Arias; Barbara E Murray Journal: Antimicrob Agents Chemother Date: 2013-06-24 Impact factor: 5.191
Authors: K-H Song; S-I Jung; S Lee; S Park; S M Kiem; S H Lee; Y G Kwak; Y K Kim; H-C Jang; Y-S Kim; H-I Kim; C J Kim; K-H Park; N J Kim; M-D Oh; H B Kim Journal: Eur J Clin Microbiol Infect Dis Date: 2016-10-06 Impact factor: 3.267
Authors: Julius Li; Kelly L Echevarria; Darrel W Hughes; Jose A Cadena; Jason E Bowling; James S Lewis Journal: Antimicrob Agents Chemother Date: 2014-06-16 Impact factor: 5.191
Authors: Y P Chong; S-J Park; E S Kim; K-M Bang; M-N Kim; S-H Kim; S-O Lee; S-H Choi; J-Y Jeong; J H Woo; Y S Kim Journal: Eur J Clin Microbiol Infect Dis Date: 2014-09-12 Impact factor: 3.267
Authors: Erlinda R Ulloa; Kavindra V Singh; Matthew Geriak; Fadi Haddad; Barbara E Murray; Victor Nizet; George Sakoulas Journal: Clin Infect Dis Date: 2020-09-12 Impact factor: 9.079